Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Inclusion Criteria:

* Must be \>- 18 years old, with a life expectancy \> 8 weeks
* Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma
* Must submit an unstained paraffin block or slides from surgical procedure
* Patients without prior treatment and with prior diagnosis of lower-grade gliomas that have been upgraded to GBM after repeated resection allowed
* At least 21 days since cranial MRI or contrast CT scan OR ≥ 96 hours since cranial MRI or contrast CT scan for patients who underwent surgical resection
* Measurable or assessable disease
* Voluntary written informed consent obtained before performance of any study related procedure not part of normal medical care.
* Karnofsky performance status \> 60%
* White Blood Count (WBC) ≥ 3,000/mm\^3
* absoulte neutrophil count(ANC) ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 10 g/dL (transfusion allowed)
* Bilirubin \< 2.5 times upper limit of normal (ULN)
* serum glutamic-oxaloacetic transaminase (SGOT) \< 2.5 times ULN
* Creatinine \< 1.5 mg/dL
* Creatinine clearance ≥ 20 mL/minute
* Serum sodium \> 130 mmol/L
* Negative pregnancy test
* Fertile patients must use effective contraception
* Patients on Enzyme-Inducing Antiepileptic Drugs (EIAED) must be transitioned to non- EAIED for ≥ 2 weeks
* Concurrent full-dose warfarin or its equivalent (e.g., unfractionated and/or low molecular weight heparin) allowed

Exclusion Criteria:

* peripheral neuropathy ≥ grade 2
* Myocardial infarction within the past 6 months
* New York Heart Association (NYHA) class III or IV heart failure
* Uncontrolled angina
* Severe uncontrolled ventricular arrhythmias
* Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
* hypersensitivity to bortezomib, boron, or mannitol
* serious medical or psychiatric illness that would interfere with study participation including, but not limited to, any of the following:
* Ongoing or active infection requiring IV antibiotics
* Psychiatric illness and/or social situations that would limit compliance with study requirements
* Disorders associated with a significant immunocompromised state (e.g., HIV, systemic lupus erythematosus)
* history of stroke within the past 6 months
* other malignancy within the past 3 years except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy (i.e., cervical cancer), or low-risk prostate cancer after curative therapy
* significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
* disease that will obscure toxicity or dangerously alter drug metabolism
* viral hepatitis (HBV surface antigen positive) or active hepatitis C infection
* Prior or concurrent corticosteroids, automated external defibrillator, analgesics, and other drugs to treat symptoms or prevent complications allowed
* concurrent investigational drugs that must be stopped at least 4 months prior to therapy.
* prior radiotherapy to the brain
* prior cytotoxic or noncytotoxic drug therapy or experimental drug therapy (including chemotherapy, hormonal therapy, or immunotherapy) directed against the brain tumor
* prior polifeprosan 20 with carmustine implant (Gliadel wafer)
* concurrent stereotactic radiosurgery or brachytherapy
* concurrent sargramostim
* concurrent inducers of CYP450 3A4 (e.g., enzyme-inducing anti-epileptic drugs \[EIAED\])